Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.19), FiscalAI reports.
Aardvark Therapeutics Stock Performance
AARD traded down $0.19 during midday trading on Friday, hitting $1.33. The stock had a trading volume of 402,447 shares, compared to its average volume of 1,698,199. Aardvark Therapeutics has a 1 year low of $0.93 and a 1 year high of $16.60. The business has a fifty day moving average of $3.76 and a 200 day moving average of $5.72. The company has a market cap of $29.10 million, a P/E ratio of -0.41 and a beta of 4.38.
Analyst Ratings Changes
Several research firms have recently weighed in on AARD. Raymond James Financial restated a “market perform” rating on shares of Aardvark Therapeutics in a research report on Friday. HC Wainwright cut their target price on shares of Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating for the company in a research report on Monday, October 26th. UBS Group set a $4.00 target price on shares of Aardvark Therapeutics in a research report on Monday, October 19th. Oppenheimer cut Aardvark Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, October 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Tuesday, September 29th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $11.56.
Insider Activity at Aardvark Therapeutics
In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the transaction, the insider directly owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 17.80% of the company’s stock.
Institutional Investors Weigh In On Aardvark Therapeutics
A number of institutional investors have recently made changes to their positions in AARD. BlackRock Inc. purchased a new position in Aardvark Therapeutics in the 2nd quarter worth $1,077,000. Marshall Wace LLP lifted its stake in Aardvark Therapeutics by 593.0% in the third quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock worth $697,000 after purchasing an additional 113,128 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Aardvark Therapeutics during the first quarter valued at about $267,000. J. Goldman & Co LP purchased a new stake in Aardvark Therapeutics during the second quarter valued at about $233,000. Finally, Ieq Capital LLC bought a new position in shares of Aardvark Therapeutics during the second quarter valued at about $221,000.
Aardvark Therapeutics Company Profile
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
Read More
- Five stocks we like better than Aardvark Therapeutics
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
